NAMED PATIENT PROGRAM USE OF PEDMARK® TO REDUCE THE RISK OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS WITH VARIED SOLID TUMORS
Loading...
Date
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
dc.identifier.other
WOS:001183650902072
dc.description.volume
dc.description.issue
Publisher
WILEY